Current Status for Oral Platinum (IV) Anticancer Drug Development  

作　　者：Qian Mi Shunshun Shu Caixia Yang Chuan Gao Xian Zhang Xiao Luo Chonghuan Bao Xia Zhang Jun Niu 

机构地区：[1]Quality Inspection and Control Center, C.P. Food ( Xiangyang) Co., Ltd., Xiangzhou District, Xiangyang, China

出　　处：《International Journal of Medical Physics, Clinical Engineering and Radiation Oncology》2018年第2期231-247,共17页医学物理学、临床工程、放射肿瘤学（英文）

摘　　要：Platinum-based chemotherapeutic drugs such as cisplatin, carboplatin and oxaliplatin are widely applied for the treatment of various types of tumors. However, poor solubility, serious side effects, and more importantly, the intrinsic and acquired resistance limit their clinical applications. These factors motivate scientists to design and synthesize novel and more potent analogues lacking disadvantages of clinical platinum drugs. Platinum (IV) complexes are one of representatives. In this review, we summarized the investigations undertaken into Platinum (IV) antitumor compounds since Rosenberg first noted their antitumor activity. The synthesis method and mechanism of action of Platinum (IV) complexes are outlined, as well as their chemical and pharmacological properties. Recent advances in Platinum (IV) anticancer agents that have been in clinical trials and photoactivatable Platinum (IV) complexes are also summarized, and the purpose here is to provide insight into the requirements for the antitumor activity of Platinum (IV) complexes and a basis for progressing in a new platinum compound.Platinum-based chemotherapeutic drugs such as cisplatin, carboplatin and oxaliplatin are widely applied for the treatment of various types of tumors. However, poor solubility, serious side effects, and more importantly, the intrinsic and acquired resistance limit their clinical applications. These factors motivate scientists to design and synthesize novel and more potent analogues lacking disadvantages of clinical platinum drugs. Platinum (IV) complexes are one of representatives. In this review, we summarized the investigations undertaken into Platinum (IV) antitumor compounds since Rosenberg first noted their antitumor activity. The synthesis method and mechanism of action of Platinum (IV) complexes are outlined, as well as their chemical and pharmacological properties. Recent advances in Platinum (IV) anticancer agents that have been in clinical trials and photoactivatable Platinum (IV) complexes are also summarized, and the purpose here is to provide insight into the requirements for the antitumor activity of Platinum (IV) complexes and a basis for progressing in a new platinum compound.

关 键 词：PLATINUM (IV) COMPLEXES Properties Mechanism ANTITUMOR Activity Cancer THERAPY Photoactivatable 

分 类 号：R73[医药卫生—肿瘤]